Aurobindo Pharma Limited has commissioned four state-of-the-art manufacturing facilities for PenicillinG, 6-Amino Penicillanic Acid (6-APA), Injectable products and Granulation, through its wholly owned subsidiaries, the company informed the Stock Exchange.

These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.

Lyfius Pharma’s plant situated in Kakinada SEZ area, Andhra Pradesh is set to manufacture (Pen - G) and Glucose having annual production capacity of 15,000 MT and 180,000 MT respectively.

Qule Pharma’s plant situated in Kakinada SEZ area, Andhra Pradesh is set to manufacture 6- Amino Penicillanic Acid (6-APA) with an annual production capacity of 3,600 MT.

Eugia Steriles Private Limited's plant situated in Tadi Village, Anakapalli District, Andhra Pradesh, will manufacture Vials/Ampoules with an annual capacity of 285 million for exports.

Auroactive Pharma Private Limited's plant situated in Sancham Village, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh, will produce Granulated products (Ready to Compress) with an annual production capacity of 13,200 MT.

The business of the respective entities has commenced by undertaking commercial production of the products. Based on the purchase orders received, the respective companies have made commercial sale to its customers. The business’ revenues and profitability of the respective entities are expected to grow over a period of time.